Transcatheter aortic valve replacement therapies have been gaining ground over the past several years as Edwards Lifesciences and Medtronic have introduced competing TAVR valves in the U.S. even as Europe boasts more players and approved products.
As this therapy gathers clinical evidence, a market forecast is available.
In a research note on Thursday, Glenn Novarro, an analyst with RBC Capital Markets, wrote that once more lower risk people with aortic stenosis are brought into the fold of TAVR, the global market will be worth $5.5 billion by 2020.
So why is TAVR gaining ground? Replacing diseased heart valves typically require surgeons to break and rib and perform invasive, open heart surgery. But many patients are too sick to endure the physical trauma of open heart surgery and some are plain inoperable.
And that latter group of patients have been where TAVR made its mark first. The procedure uses